Operator Ladies and gentlemen, thank you for standing by and welcome to the Lilly Q4 2024 earnings call. [Operator ...

Lilly's fourth-quarter profit doubles, driven by diabetes and obesity treatments. Strong revenue and forecast for 2025.

Eli Lilly stock is higher Thursday after the pharma giant beat fourth-quarter profit expectations and issued strong 2025 ...

Eli Lilly & Co.’s full-year earnings forecast came in line with analysts’ estimates as the company works to fix inventory problems with its new blockbuster obesity and diabetes drugs that weighed on ...

Eli Lilly & Co. said its Type-2 Diabetes drug Mounjaro and weight-loss/diabetes medicine Zepbound drove a 45% increase in fourth-quarter revenue to $13.53 billion.

Both have been unexpected, and upsetting, side-effects of my decision last year to become one of the thousands of women turning to the weight-loss jab Mounjaro. I've heard of other users ...

Demand has rocketed for slimming injections such as ­Ozempic and Mounjaro, known as GLP-1 receptor agonists. Researchers found people taking the jabs had lower rates of 42 ­conditions ...

Shares of Eli Lilly & Co. were headed for their worst day in nearly four years on Tuesday after the drugmaker provided a fourth-quarter revenue outlook that was below expectations, citing slower ...

In the company's third-quarter report in October, Lilly reported sales of both Mounjaro and Zepbound that ... which is operated by Dow Jones & Co. MarketWatch is published independently from ...